Given the limitations of current antiviral therapies, safer and more effective approaches to the management of recurrent herpes labialis (RHL) are needed.
Methods
A patient with a 23-year history of RHL and 14 healthy individuals were studied. The patient applied imiquimod to distant healthy skin for 3 weeks. Peripheral blood (PB) samples were collected from the patient during treatment and 21 months after its discontinuation; samples were collected from the controls once. The distribution of lymphocyte populations in PB were analysed by flow cytometry and PB cytokine levels were measured using cytometric bead arrays.
Results
The patient showed long-term remission of the disorder subsequent to a 3-week imiquimod application to distant healthy skin. Imiquimod treatment induced the activation and proliferation of T-helper and cytotoxic T-cells, B-cells and T-regulatory cells. In addition, there was a very strong transient increase of T-helper 1 cells (resulting in interferon-γ secretion) and type 1 (pro- inflammatory) polarization of the immune response accompanied by a sustainable interferon-α production. At follow-up 21 months after treatment cessation, with the patient remaining relapse-free, the patient had control levels of all cytokines, increased levels of activated cytotoxic T-cells, continuous production of new T-helper cells and B-cells and near-to-normal levels of T-regulatory cells.
Conclusions
Our results indicate that topical application of imiquimod to healthy skin is capable of causing systemic immunomodulation. This treatment might represent a new and effective alternative to established therapeutic and prophylactic regimens for RHL.
References
1.
SpruanceS.L., KrieselJ.D.Treatment of herpes simplex labialis. Herpes2002; 9: 64–69.
2.
GilbertS., CoreyL., CunninghamA.An update on short-course intermittent and prevention therapies for herpes labialis. Herpes2007; 14Suppl 1: 13A–18A.
3.
St PierreS.A., BartlettB.L., SchlosserB.J.Practical management measures for patients with recurrent herpes labialis. Skin Therapy Lett2009; 14: 1–3.
CernikC., GallinaK., BrodellR.T.The treatment of herpes simplex infections. An evidence-based review. Arch Intern Med2008; 168: 1137–1144.
6.
FemianoF., GombosF., ScullyC.Recurrent herpes labialis: a pilot study of the efficacy of zinc therapy. J Oral Pathol Med2005; 34: 423–425.
7.
McKennaD.B., NeillW.A., NorvalM.Herpes simplex virus-specific immune responses in subjects with frequent and infrequent orofacial recrudescences. Br J Dermatol2001; 144: 459–464.
8.
SauderD.N.Immunomodulatory and pharmacologic properties of imiquimod. J Am Acad Dermatol2000; 43: S6–S11.
9.
SchönM.P., SchönM.TLR7 and TLR8 as targets in cancer therapy. Oncogene2008; 27: 190–199.
10.
AdamsS., O'NeillD.W., NonakaD.Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J Immunol2008; 181: 776–784.
11.
BernsteinD.I., HarrisonC.J.Effects of the immunomodulating agent R837 on acute and latent herpes simplex virus type 2 infections. Antimicrob Agents Chemother1989; 33: 1511–1515.
12.
HarrisonC.J., MillerR.L., BernsteinD.I.Posttherapy suppression of genital herpes simplex virus (HSV) recurrences and enhancement of HSV-specific T-cell memory by imiquimod in guinea pigs. Antimicrob Agents Chemother1994; 38: 2059–2064.
13.
PasmatziE., ChaidaroglouA., SakkisTh. Topical application of imiquimod induces alterations in peripheral blood lymphocytes in healthy individuals. Acta Derm Venereol2009; 89: 134–139.
14.
HemmiH., KaishoT., TakeuchiO.Small anti-viral compounds activate immune cells via the TLR7My88-signaling pathway. Nat Immunol2002; 3: 196–200.
15.
BiluD., SauderD.N.Imiquimod:modes of action. Br J Dermatol2003; 149: 5–8.
16.
HarrisonC.J., JenskiL., VoychehovskiT., BernsteinD.I.Modification of immunological responses and clinical disease during topical R-837 treatment of genital HSV-2 infection. Antiviral Res1988; 10: 209–223.
17.
BernsteinD.I., MillerR.I., HarrisonC.J.Adjuvant effects of imiquimod on a herpes simplex type 2 glycoprotein vaccine in guinea pigs. J Infect Dis1993; 167: 731–735.
18.
BernsteinD.I., HarrisonC.J., TepeE.R., ShahwanA., MillerR.L.Effect of imiquimod as adjuvant for immunotherapy of genital HSV in guinea-pigs. Vaccine1995; 13: 72–76.
19.
MillerR.L., ReiterM.J., GersterJ.F.Treatment of primary herpes simplex virus infection in guinea pigs by imiquimod. Antiviral Res1999; 44: 31–42.
20.
BernsteinD.I., SpruanceS.L., AroraS.S., SchroederJ.L., MengT.C.Evaluation of imiquimod 5% cream to modify the natural history of herpes labialis: a pilot study. Clin Infect Dis2005; 41: 808–814.
BensonE.Imiquimod:potential risk of an immunostimulant. Australas J Dermatol2004; 45: 123–124.
24.
GillietM., ConradC., GeigesM.Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors. Arch Dermatol2004; 140: 1490–1495.
25.
FantiP.A., DikaE., VaccariS., MiscialC., VarottiC.Generalized psoriasis induced by topical treatment of actinic keratosis with imiquimod. Int J Dermatol2006; 45: 1464–1465.
26.
RajanN., LangtryJ.A.Generalized exacerbation of psoriasis associated with imiquimod cream treatment of superficial basal cell carcinomas. Clin Exp Dermatol2006; 31: 140–141.
27.
WangQ., McLoughlinR.M., CobbB.A.A bacterial carbohydrate links innate and adaptive responses through Toll-like receptor 2. J Exp Med2006; 203: 2853–2863.
28.
YoshidaA., KohchiC., InagawaH., NishizawaT., SomaG.Improvement of allergic dermatitis via regulation of the Th1/Th2 immune system balance by macrophages activated with lipopolysaccharide derived from Pantoea agglomerans (IP-PA1). Anticancer Res2009; 29: 4867–4870.
29.
SainzB.Jr., HalfordW.P.Alpha/Beta interferon and gamma interferon synergize to inhibit the replication of herpes simplex virus type 1. J Virol2002; 76: 11541–11550.
30.
CunninghamA.L., DiefenbachR.J., Miranda-SaksenaM.The cycle of human herpes simplex virus infection: virus transport and immune control. J Infect Dis2006; 194Suppl 1: S11–S18.
31.
PengT., ZhuJ., KlockA.Evasion of the mucosal innate immune system by herpes simplex virus type 2. J Virol2009; 83: 12559–12568.
32.
KantorA.B.The development and repertoire of B-1 cells (CD5 B cells). Immunol Today1991; 12: 389–391.
33.
BaumgarthN., TungJ.W., HerzenbergL.A.Inherent specificities in natural antibodies: a key to immune defence against pathogen invasion. Springer Semin Immunopathol2005; 26: 347–362.
34.
DemirkiranA., HendrikxT.K., BaanC.C., van der LaanL.J.Impact of immunosuppressive drugs on CD4+CD25+FOXP3+ regulatory T cells: does in vitro evidence translate to clinical settings?Transplantation2008; 85: 783–789.
35.
ChenX., OppenheimJ.J.TNF-alpha: an activator of CD4+FoxP3+TNFR2+ regulatory T cells. Curr Dir Autoimmun2010; 11: 119–134.
36.
LassusA., BergelinI., PalorantaA., RinneE., EskelinenA., SäiläK.Efficacy of interferon and placebo in the treatment of recurrent genital herpes: a double-blind trial. Sex Transm Dis1987; 14: 185–190.
